Posts

Altimmune’s Next-Gen GLP-1 Curbs Heavy Drinking in Unequivocal Phase 2 alcohol use disorder win

on

Digital tool to help identify cancer patients at risk of serious immunotherapy side effect

on

Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks

on

Outfront Health Appoints Dr. Shane Speirs as Chief Medical Officer

on

Consequences of Alternative Funding Programs for Specialty Drugs: Patient Risks and Industry Concerns

on

Shadow AI in Healthcare 2026: Dos and Don'ts for Organizations

on

Eli Lilly Warns of Dangerous Impurity in Compounded Tirzepatide with Vitamin B12

on

Ipsen Withdraws Cancer Drug Tazverik from Market Due to Secondary Blood Cancer Risks

on

FDA delays decision date on Cytokinetics' heart drug to year-end in unusual safety program back-and-forth

on

UK approval brings GSK's Blenrep back from the brink

on

ViiV Healthcare's Multifaceted Approach to Combating HIV in Black Communities

on

FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

on